BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schindler P, Seifert L, Masthoff M, Riegel A, Köhler M, Wilms C, Schmidt HH, Heinzow H, Wildgruber M. TIPS Modification in the Management of Shunt-Induced Hepatic Encephalopathy: Analysis of Predictive Factors and Outcome with Shunt Modification. J Clin Med 2020;9:E567. [PMID: 32092979 DOI: 10.3390/jcm9020567] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Huang Z, Yao Q, Zhu J, He Y, Chen Y, Wu F, Hua T. Efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPS) created using covered stents of different diameters: A systematic review and meta-analysis. Diagn Interv Imaging 2021;102:279-85. [PMID: 33303394 DOI: 10.1016/j.diii.2020.11.004] [Reference Citation Analysis]
2 Seifert LL, Schindler P, Schoster M, Weller JF, Wilms C, Schmidt HH, Maschmeier M, Masthoff M, Köhler M, Heinzow H, Wildgruber M. Recurrence of Hepatic Encephalopathy after TIPS: Effective Prophylaxis with Combination of Lactulose and Rifaximin. J Clin Med 2021;10:4763. [PMID: 34682886 DOI: 10.3390/jcm10204763] [Reference Citation Analysis]
3 Khan A, Bailey CW. Unique Method of Transjugular Intrahepatic Portosystemic Shunt Reduction for Refractory Hepatic Encephalopathy. Cureus 2021;13:e18838. [PMID: 34804693 DOI: 10.7759/cureus.18838] [Reference Citation Analysis]
4 Schindler P, Heinzow H, Trebicka J, Wildgruber M. Shunt-Induced Hepatic Encephalopathy in TIPS: Current Approaches and Clinical Challenges. J Clin Med 2020;9:E3784. [PMID: 33238576 DOI: 10.3390/jcm9113784] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Praktiknjo M, Abu-Omar J, Chang J, Thomas D, Jansen C, Kupczyk P, Schepis F, Garcia-Pagan JC, Merli M, Meyer C, Strassburg CP, Pieper CC, Trebicka J. Controlled underdilation using novel VIATORR® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation. JHEP Rep 2021;3:100264. [PMID: 34013182 DOI: 10.1016/j.jhepr.2021.100264] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
6 Krishnamurthy P, Ahmad A. Successful treatment of recurrent hepatic encephalopathy with revision of transjugular intrahepatic portasystemic shunt and embolisation of splenorenal shunt. BMJ Case Rep 2021;14:e242368. [PMID: 34167979 DOI: 10.1136/bcr-2021-242368] [Reference Citation Analysis]
7 Takaya H, Namisaki T, Sato S, Kaji K, Tsuji Y, Kaya D, Fujinaga Y, Sawada Y, Shimozato N, Kawaratani H, Moriya K, Akahane T, Mitoro A, Yoshiji H. Increased Endotoxin Activity Is Associated with the Risk of Developing Acute-on-Chronic Liver Failure. J Clin Med. 2020;9. [PMID: 32422875 DOI: 10.3390/jcm9051467] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Seifert LL, Görlich D, Jansen C, Ortmann O, Schoster M, Praktiknjo M, Gu W, Schindler P, Köhler M, Maschmeier M, Wilms C, Meyer C, Schmidt HH, Wildgruber M, Trebicka J, Heinzow H. Evaluation of impact of elective invasive examinations in patients with transjugular intrahepatic portosystemic shunt in the long-term follow up. Z Gastroenterol 2021;59:24-34. [PMID: 33429447 DOI: 10.1055/a-1330-9867] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]